ResourceLife Sciences
Pre-clinical evaluation of potential cytokine release syndrome and efficacy of a BCMAxCD3 bispecific antibody in humanized mice
15 Mar 2021Bispecific antibodies (BsAbs) are now emerging as the next promising class of immunotherapies.
As BsAbs can have significant adverse effects such as cytokine release syndrome (CRS), the Jackson Laboratory decided to evaluate the CRS related safety profile, in addition to efficacy, of this BCMAxCD3 BsAb in pre-clinical studies.
Links
Tags
AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.Animal ModelsThe use of non-human animals in experiments or behavorial observations. The research is conducted inside universities, medical schools, pharmaceutical companies, farms, defence establishments, and commercial facilities that provide animal-testing services to industry. It includes pure research such as genetics, developmental biology, behavioral studies, as well as applied research such as pharmaceutical testing in pre-clinical, before human, studies. CytokinesCytokines are signaling proteins critical for cell communication in the immune system. They regulate inflammation, immune responses, and cell growth. Cytokine research is vital for understanding disease mechanisms and developing therapies. Explore tools for cytokine detection and analysis in our directory.